The U.S. Food and Drug Administration has cleared the way for the world’s first study of human embryonic stem cell therapy, Geron Corp said on Friday.
The California biotechnology company plans to start a clinical trial to try to use the stem cells to regrow nerve tissue in patients with acute spinal cord injury.
“This marks the beginning of what is potentially a new chapter in medical therapeutics — one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function achieved by the injection of healthy replacement cells,” Geron Chief Executive Thomas Okarma said in a statement.
O that's right, I forgot, we have someone with a brain in the White House again.
No comments:
Post a Comment